Chapter 26.Olanzapine
Sections
Excerpt
The story of specific antipsychotic medications for patients with schizophrenia and other severe psychiatric illnesses began in the early 1950s, when chlorpromazine was first given to psychotic patients in France (Delay and Bernitzer 1952). The antipsychotic qualities of this compound, as well as its “tranquilizing” effect, were dramatic and substantial. Studies performed around the world during the 1950s showed the usefulness of this new compound and of the others that followed. As is well known, multicenter trials of antipsychotic medications found that the approved medications were substantially and significantly better than placebo (Guttmacher et al. 1964). Furthermore, despite the range of chemical structures, the clinical effects were similar. In addition, the need to investigate the new medications for psychiatric illness led to improved clinical trial methodology for the field. During the 1960s, randomized and placebo-controlled trials became the standard for assessing the new medications for schizophrenia. These trials led to adoption of antipsychotic medications as the standard somatic treatment for schizophrenia.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).